1Alatas F, Alatas O, Metintaas M, et al. Diagnostic value of CEA,CA153,CA199,CYFRA21-1,NSE and TSA assay in pleural effusions [J].Lung Cancer, 2001,31(1):9--16.
2Ando S,Kimura H,Iwai N,et al. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer [J].Anticancer Res, 2001,21 (413) : 3085--3092.
3Trape J, Buxo J, Perez OJ, et al. Tumor markers as prognostic factors in treated non-small cell lung cancer[J]. Anticancer Res, 2003,23 (56) :4277-- 4281.
4Baughman RP, Lower EE. An inhibitor of tumor necrosis fator found in pleural effusions [J].J Lab Clin Med, 1991,118(2) : 326-- 331.
5Trap J, Buxo J, Prrezde J, et al. Tumor markers prognostic factors in treated non-small cell lung cancer [J]. Anticancer Res, 2003,23(5b) 14277--4281.
6Pujol JL, Boher JM, Grenier J, et al. Cyfra21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients [J]. Lung Cancer, 2001,31 (2) : 221 -- 231.
8[5]Hogdall EV, Christensen L, Kjaer SK,et al. Distribution of HER - 2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma:from the Danish MALOVA Ovarian Cancer Study[J]. Cancer, 2003,98(1):66-73.
9[8]Coiffier B,Lepage E,Briere J,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large- B- cell lymphoma[J]. N Eng1 J Med, 2002, 346(4) :235 - 242.
10[9]Ansell SM,Witzig TE,Kurtin PJ,et al.phase 1 study of interleukin - 12 in combination with rituximab in patients with B - cell non - Hodgkin lymphoma[J]. Blood, 2002, 99(1): 67 - 74.
